Alleviated symptoms of SARS‐CoV‐2 Omicron variant infection in chronic hepatitis B patients with immune control

Abstract

AbstractThe impact of hepatitis B virus (HBV) infection on the progression of coronavirus disease 2019 (COVID‐19) disease remains controversial. We aimed to investigate whether pre‐existing chronic HBV (CHB) infection and therapy with anti‐HBV nucleos(t)ide analogs (NAs) influence the clinical presentation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant infection. In this study, clinical information was collected via a questionnaire from patients with COVID‐19, and their clinical symptoms were quantitatively assessed for comparative analyses. Additionally, hepatitis B‐related laboratory data were collected for CHB patients. Propensity score matching (PSM) was used to minimize confounding biases. A total of 785 patients with COVID‐19 were included in the cohort, of which 387 were identified as being infected with CHB infection and they were categorized as being in the immune control or clearance phase. After PSM, the CHB group (n = 222) had a shorter duration of fever and disease course, milder clinical symptoms, and lower incidence of pneumonia than the non‐CHB group (n = 222) after Omicron variant infection (p < 0.05). After the adjustment of confounding factors, CHB patients showed a lower risk of prolonged fever, severe clinical symptoms, and pneumonia (p < 0.05). However, there were no statistically significant differences in the clinical symptoms and incidence of pneumonia between CHB patients who received and did not receive NAs, or CHB patients who received tenofovir disoproxil fumarate and entecavir (p > 0.05). In conclusion, our findings suggest that the crosstalk of anti‐HBV immunity may contribute to the alleviated symptoms of SARS‐CoV‐2 Omicron variants infection in the CHB patients, independent of anti‐HBV NA therapy.